The Fukuoka Kidney disease Registry (FKR) Study: design and methods
The Fukuoka Kidney disease Registry (FKR) Study: design and methods
复制标题
DOI：
10.1007/s10157-016-1294-4
复制
发表时间：
2017-06-01
影响因子：
2.3
通讯作者：
Tsuruya, Kazuhiko
中科院分区：
文献类型：
--
作者：
Tanaka, Shigeru;Ninomiya, Toshiharu;Tsuruya, Kazuhiko
慢性肾脏疾病（CKD）是进展为终末期肾脏疾病（ESRD）和心血管疾病（CVD）发生率的既定独立风险因素。CKD的发病和进展与遗传易感性和各种生活方式相关因素有关，但关于遗传-环境相互作用对CKD患者ESRD或CVD发病率的影响知之甚少。福冈肾脏病登记（FKR）研究是在非透析依赖性CKD患者中进行的最大的前瞻性、多中心、观察性队列研究之一。FKR研究旨在在多个临床中心招募约5000名受试者，并对他们进行至少5年的随访。在基线时，入组FKR研究的受试者将填写广泛的生活方式相关问卷。此外，他们的健康状况和治疗将每年通过肾脏病中心的研究网络进行监测。将在入组时和每5年随访时采集血液和尿液样本，包括DNA/RNA。FKR研究将提供对CKD发病和进展的许多见解，这将建议旨在减轻CKD负担的假设驱动的干预性临床试验。FKR研究的特点也可能促进创新研究，以通过高通量组学技术使用生物材料识别和验证新的风险因素，包括遗传易感性和生物标志物。
Chronic kidney disease (CKD) is an established independent risk factor for progression to end-stage renal disease (ESRD) and incidence of cardiovascular disease (CVD). The onset and progression of CKD are associated with both genetic predisposition and various lifestyle-related factors, but little is known about the influence of genetic-environmental interactions on the incidence of ESRD or CVD in patients with CKD.The Fukuoka Kidney disease Registry (FKR) Study is designed as one of the largest prospective, multicenter, observational cohort studies in non-dialysis dependent CKD patients. The FKR Study aims to enroll approximately 5000 individuals at multiple clinical centers and follow them for up to at least 5 years. At baseline, subjects enrolled in the FKR Study will fill out extensive lifestyle-related questionnaires. Further, their health status and treatments will be monitored annually through a research network of nephrology centers. Blood and urine samples, including DNA/RNA, will be collected at the time of enrolment and every 5-years follow-up.The FKR Study will provide many insights into the onset and progression of CKD, which will suggest hypothesis-driven interventional clinical trials aimed at reducing the burden of CKD. The features of the FKR Study may also facilitate innovative research to identify and validate novel risk factors, including genetic susceptibility and biomarkers, using biomaterials by high-throughput omics technologies.